Raising for Raze

Atlas Venture built platform company Raze Therapeutics Inc. to explore multiple targets and pathways associated with mitochondrial one-carbon metabolism, which the company thinks will supply novel targets to treat more cancers with fewer side effects than other products targeting tumor metabolism.

Atlas, MPM Capital, MS Ventures, Partners Innovation Fund, Astellas Venture Management and Novartis AG (NYSE:NVS; SIX:NOVN) each contributed to Raze's $24 million series A round announced last week...